Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | IL1B | P01584 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15516633 | 1.00 | PDE8B (0.40) | PDE8BALOX5APJAK2ALDH1A1FEN1 | |
| SCHEMBL16492427 | 0.89 | PDE8B (0.39) | PDE8BALOX5APJAK2ALDH1A1FEN1 | |
| SCHEMBL16492428 | 0.89 | PDE8B (0.39) | PDE8BALOX5APJAK2ALDH1A1FEN1 | |
| SCHEMBL13860102 | 0.86 | HRH3 (0.35) | JAK3 | |
| SCHEMBL17406882 | 0.82 | GPR119 (0.43) | PIK3CDMAPT | |
| SCHEMBL15516736 | 0.82 | PDE8B (0.40) | PDE8BALOX5APJAK2ALDH1A1FEN1 | |
| SCHEMBL15516738 | 0.82 | PDE8B (0.40) | PDE8BALOX5APJAK2ALDH1A1FEN1 | |
| SCHEMBL19731422 | 0.79 | IL1B (0.44) | PDE8BALDH1A1IL1BP2RX7IRAK4 | |
| SCHEMBL13857901 | 0.76 | IL1B (0.43) | PDE8BALOX5APALDH1A1FEN1IL1B | |
| SCHEMBL18925739 | 0.76 | IL1B (0.43) | PDE8BALOX5APALDH1A1FEN1IL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9572811-B2 | Treatment of dry eye | PRINCIPIA BIOPHARMA INC. (US) | 2017-02-21 | — | — | US | disclosed |
| EP-2710005-B1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-9376438-B2 | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160045503-A1 | FORMULATIONS CONTAINING REVERSIBLE COVALENT COMPOUNDS | PRINCIPIA BIOPHARMA INC. | 2016-02-18 | — | — | US | disclosed |
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353562-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-9090621-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20150182530-A1 | TREATMENT OF DRY EYE | PRINCIPIA BIOPHARMA INC. (US) | 2015-07-02 | — | — | US | disclosed |
| US-8962831-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962635-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8957080-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8946241-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140336382-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140309223-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140303161-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140303190-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140221398-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8759358-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8673925-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-03-18 | — | — | US | disclosed |
| WO-2014022569-A1 | TREATMENT OF DRY EYE | PRINCIPIA BIOPHARMA INC. (US) | 2014-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | PDE8B 2187/4885ALOX5AP 1946/4885JAK2 23/4885 |
| US-20140303161-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | PDE8B 2187/4885ALOX5AP 1946/4885JAK2 23/4885 |
| US-20150353562-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | PDE8B 2187/4885ALOX5AP 1946/4885JAK2 23/4885 |
| US-20160045503-A1 | FORMULATIONS CONTAINING REVERSIBLE COVALENT COMPOUNDS | PTMS, SSB, HDAC6 | PDE8B 1180/4885ALOX5AP 408/4885JAK2 979/4885 |
| US-20140303190-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | PDE8B 2187/4885ALOX5AP 1946/4885JAK2 23/4885 |
| US-20140336382-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | PDE8B 2187/4885ALOX5AP 1946/4885JAK2 23/4885 |
| US-20140221398-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | BMX, BLK, TEC | PDE8B 1952/4885ALOX5AP 2254/4885JAK2 11/4885 |
| US-20140309223-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | PDE8B 2187/4885ALOX5AP 1946/4885JAK2 23/4885 |
| US-20150182530-A1 | TREATMENT OF DRY EYE | BTK, SYK, LYN | PDE8B 1565/4885ALOX5AP 1125/4885JAK2 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.